Celericon Therapeutics GmbH was founded on 1st March 2018 and is registered in Salzburg/Austria as a 100% subsidiary of the Paracelsus Medical University Salzburg – private foundation (PMU), prepared to work with scientific and commercial partners.

PMU engages actively in research and development of Molecular and Cellular / Exosome based Therapeutics since 2011.

Celericon Therapeutics GmbH is the hub of the PMU to engage in commercialisation of its research and development products.